More than $10 million in taxpayer dollars saved by proactively addressing CGM nonadherence in thousands of Medicare patients with diabetes

More than a third of this high-risk population experiences improved adherence resulting from AI-powered personalized interventions

ST. PETERSBURG, Fla.: #chroniccare--CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, announced new data-driven findings that show the company’s proprietary AI-enabled predictive analytics and intervention platform — PropheSee™ — effectively identified approximately 28 percent of 55,000 Medicare fee-for-service (FFS) patients at risk of lapsing on continuous glucose monitoring (CGM) therapy. As a result of applying CCS’s predictive analytics and intervention platform to this high-risk Medicare population, more than $10 million in taxpayer dollars have already been saved.

After identifying more than 14,400 at-risk patients, CCS then segmented them into defined personas based on patient-specific clinical, socioeconomic, and behavioral data. Customized interventions designed to effect lasting behavior change were then deployed, leading to millions of taxpayer dollars being saved in unused CGM devices and unnecessary care for this high-cost, high-risk population.

The following two interventions illustrate the striking impact of PropheSee™ on Medicare patients’ CGM adherence:

• Adherence improved 46% when patients received messages aligned with provider trust.
• Rural patients showed a 30% adherence boost when reminded of at-home support options.

PropheSee™, launched in June 2024, was awarded “Best Predictive Analytics Solution” as part of the MedTech Breakthrough Awards on May 8, 2025 — a prestigious international awards program that recognizes exceptional digital health and medical technology products and companies. The platform is a first-of-its-kind AI-powered predictive and intervention platform that actively identifies patients most at risk of stopping usage of their CGM within 30 days with 85% accuracy and deploys highly personalized interventions to keep these patients on track.

By moving the signal and intervention upstream with PropheSee™, CCS can help patients and providers stay one step ahead of nonadherence. By keeping people on CGM therapy who may otherwise have experienced adverse consequences of poor glycemic control, health plans and risk-bearing providers can realize improved clinical outcomes, a reduction in high-cost utilization (such as emergency room visits), and savings of up to $2,200 per patient per year.

President of Lumeris Technology Solutions and CTO of Lumeris, Jean-Claude Saghbini, shared his thoughts on the value of providers like CCS expanding their role in the chronic care continuum: “For years, healthcare leaders have talked about the massive human and cost impact of being able to prevent care crises before they happen. With AI, that opportunity is now, and companies like CCS are at the forefront of supporting health plans and at-risk providers in moving from sick care to preventive care, starting with CGM adherence and the application of sound clinical and lifestyle support for the highest complexity and highest cost patient populations.”

CCS has invested heavily in reimagining the role of distributors in supporting the move to value-driven, proactive, and personalized diabetes care management. In addition to the latest Medicare FFS findings tied to the company’s predictive analytics and intervention platform, CCS has also taken a leadership role in pursuing evidence-based research that proves the value of suppliers in chronic care management. Most recently, CCS published research in Clinical Diabetes and in JMIR Diabetes — showcasing how suppliers, like CCS, produce superior outcomes compared to pharmacies when supporting patients using CGMs because they provide the clinical education and coaching needed to help patients with diabetes thrive.

“To combat the growing diabetes epidemic, we must focus on improving patient adherence and recognizing providers like CCS as essential members of the care ecosystem,” said Tony Vahedian, CEO of CCS. “As a specialized care provider, CCS has proven it can deliver vital diabetes interventions directly to the patient, improving outcomes and reducing costs for high-risk populations while saving taxpayers millions.”

To learn more about CCS’s transition from traditional supplier to an intelligent, holistic chronic care management platform that bridges costly gaps in patient-facing chronic care education and coaching, visit ccsmed.com/predictive-analytics.

About CCS
CCS is a leading chronic care management company, providing clinical solutions and home-delivered medical supplies for those living with chronic conditions, particularly diabetes. The company works with health plans, providers, and employers to defragment the patient journey by combining the following into one seamless platform experience: medical devices, pharmaceuticals, and clinical education and coaching services. To holistically support individuals living with diabetes, CCS has advanced its AI-based machine learning and large language models to support high-risk members’ identification and timely engagement before serious adherence issues arise. CCS supports 200,000+ people living in the United States and delivers more than 1.2 million orders directly to their homes yearly. After serving individuals for more than 30 years, CCS has the relationships, experience, and data to create a new era of home-based, proactive chronic care management era. To learn more about CCS, please visit CCSMed.com; LinkedIn.

Fonte: Business Wire